Bulllogic (@BullLogic) header
Bulllogic (@BullLogic) profile picture

Trade it. No heartbreak allowed.

USA
Joined February 2014
Bulllogic retweeted
Sabrina I have a new project 566K float play just hit pre split low .23 or just about 4.37, bang this one all the way to 25-30 less than cash/assets at $63 per share at 36MIL $PMCB
1
3
362
Bulllogic retweeted
From a reliable source. FDA commissioner- the current front runner is Senator Roger Marshall- the same Roger Marshal who went to Mikhail to ask for Deramiocel approval. Think Mikhail will want to explain to his new boss why Deramiocel was not approve! $capr @houmanhemmati @Elijahjstacy
3
3
1
49
7,143
markets a$$ go outside and play
118
Bulllogic retweeted
We have learned that third parties who provide services to the firm were the target of a cyber attack. Based on our investigation so far, we believe the attackers accessed certain marketing data held by those vendors, which may include some customer names and email addresses. There is no disruption to our services. Where appropriate, we will contact affected customers directly and offer support, including complimentary credit monitoring. There is no connection to service disruption some customers experienced earlier this week.
658
1,603
515
7,370
2,152,188
Bulllogic retweeted
$ANT IS LIVE
1
1
79
$CAPR Approval tomorrow or Monday?
6
19
1,779
$SLS I figure it settles in the $11-12 range to come.
96
$PMCB Reminder $31 in cash a share.
95
$sls SELLAS Life Sciences Prices $150 Million Public Offering at $13 a Share. 🤮
2
8
999
Bulllogic retweeted
The odds for $CAPR Deramiocel approval are good (60%-80%). Rationale: 1) Regulatory signals: • FDA "lifted" its own July 2025 CRL and resumed review in March. Fierce Biotech called that highly unusual. • After the negative adcomm, there was no second CRL on 8/22. CBER accepted a major amendment and took three more months. 2) The filing got stronger • The indication now matches HOPE-3's primary endpoint: preservation of upper limb function. The cardiomyopathy claim the panel rejected is gone. • Two-year open-label extension data and added robustness analyses went in with the amendment. • 98 of 106 patients chose to continue into the open-label extension. • The Phase 3 results were published in The Lancet: arm function declined 54% more slowly vs placebo. 3) Context • 28 HOPE-3 physician investigators wrote to FDA leadership urging approval. • Non-ambulant DMD is a huge unmet need. • Adcomm votes are non-binding. FDA approved Elevidys and eteplirsen over reviewer objections. GLTA!
1
14
906
$capr dark pool manipulation today.
5
343
Bulllogic retweeted
*ANTHROPIC IS SAID TO PRICE IPO AT $83 PER SHARE *ANTHROPIC IS SAID TO INCREASE THE SIZE OF ITS IPO
40
43
14
679
126,601
$CAPR Share grab. Could be approval tonight.
4
14
1,299
$CAPR Hit the ground running. You saw the job posting right? CEO Marbán stated on the Q3 call: "We are going independently in preparation for launch and commercialization of deramiocel without the participation of NS Pharma at this point in any way."
112
Macaulay Culkin returns as Kevin McCallister in a new McDonalds advert for the new ‘HOME ALONE’ meal.
538
8,883
699
90,700
4,151,561
$CAPR Just remember what they did with $SLS. Shorts are gonna burn in hell AGAIN!
1
9
478
Bulllogic retweeted
ANTHROPIC’S IPO HAS DRAWN IN NEARLY $500 BILLION DOLLARS IN ORDERS ANTHROPIC PLANNED TO RAISE ONLY $64.4 BILLION FROM THE PUBLIC RETAIL INVESTORS HAVE ALONE PLANNED ORDERS WORTH $100 BILLION DOLLARS FOR THE IPO $ANT
48
37
11
828
117,556